Patent Issued for Variant IgG Fc polypeptides and uses thereof (USPTO 12030945).

A patent has been issued for variant IgG Fc polypeptides and their potential use in treating autoimmune disorders and cancer. The patent, assigned to Seismic Therapeutic Inc., describes the development of therapeutic antibodies that selectively bind to FcgRIIb, a receptor expressed on B cells. These antibodies have enhanced immunosuppressive properties and could be used as therapeutic agents for inflammatory diseases. The patent provides detailed information on the amino acid sequences and mutations associated with these variant IgG Fc polypeptides, as well as their potential pharmaceutical applications. It also mentions the use of inhibitory receptor effector domains in conjunction with the Fc polypeptides. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)